Form 4: CytomX Therapeutics CEO Sells Shares to Cover Tax Obligations
SEC Form 4
CytomX Therapeutics CEO Sean A. McCarthy sold 20,223 shares of common stock on March 19, 2024, to satisfy tax withholding obligations related to vesting restricted stock units.
Summary
- On March 19, 2024, Sean A. McCarthy, CEO of CytomX Therapeutics, sold 20,223 shares of common stock at a price of $2.0855 per share.
- The sale was executed to cover tax or government withholding obligations associated with the vesting of restricted stock units.
- Following the transaction, McCarthy directly owns 524,481 shares of common stock, including 197,500 restricted stock units.
- He also indirectly owns 93,158 shares through the Sean A. McCarthy 2018 Trust, where he serves as trustee.
Sentiment
Score: 5
Explanation: Neutral sentiment as the transaction is a routine sale to cover tax obligations and doesn't necessarily reflect a change in the executive's view of the company.
Industry Context
Sales of shares to cover tax obligations are a routine part of executive compensation and are not necessarily indicative of the executive's sentiment about the company's future prospects.
Key Dates
| Date | Description |
|---|---|
| 03/19/2024 | Date of stock sale transaction. |
| 03/21/2024 | Date of signature on the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.